The cost-effectiveness challenge: is it worth it? by Knapp, Martin
  
Martin Knapp 
The cost-effectiveness challenge: is it 
worth it? 
 
Article (Published version) 
(Refereed) 
 
 
 
 
Original citation: 
Knapp, Martin (2015) The cost-effectiveness challenge: is it worth it? Alzheimer’s Research & 
Therapy, 7 (1). pp. 1-3. ISSN 1758-9193  
 
DOI: 10.1186/s13195-015-0095-4  
 
Reuse of this item is permitted through licensing under the Creative Commons: 
 
© 2015 Knapp; licensee BioMed Central. 
CC BY 4.0 
 
This version available at: http://eprints.lse.ac.uk/60467/ 
 
Available in LSE Research Online: Online: May 2015 
 
LSE has developed LSE Research Online so that users may access research output of the 
School. Copyright © and Moral Rights for the papers on this site are retained by the individual 
authors and/or other copyright owners. You may freely distribute the URL 
(http://eprints.lse.ac.uk) of the LSE Research Online website.  
 
 
 
Knapp Alzheimer's Research & Therapy  (2015) 7:10 
DOI 10.1186/s13195-015-0095-4COMMENTARYThe cost-effectiveness challenge: is it worth it?
Martin KnappAbstract
Scarcity of resources means that difficult choices have to be made about how to use them. Cost-effectiveness
evidence provides a way to help decision-makers get ‘best value’ from their resources when choosing between two
or more clinical or other interventions. Often it is found that one intervention has better outcomes than another,
but also costs more. In these circumstances there is a need for the decision-maker to reach a view as to whether
those better outcomes are ‘worth’ the higher costs, necessitating difficult trade-offs. Illustrations from the dementia
field are given to illustrate how these trade-offs might be made. For strategic decisions it has often proved helpful
to use a generic outcome measure such as the quality-adjusted life year. The fundamental aim of a healthcare
system is not to save money, but to save and improve lives. Cost-effectiveness and similar analyses can help by
showing how to get the most out of available resources.Introduction
There are never enough resources to meet everyone’s
health or other needs, or to satisfy everyone’s wants. Con-
sequently, anyone taking decisions on how to spend avail-
able resources faces some tough choices. Payers, hospital
managers and other healthcare decision-makers generally
want to use their budgets to achieve the best outcomes
they can: meeting patients’ needs, reducing symptoms and
improving quality of life. But converting available re-
sources into best outcomes is no easy feat.
Increasingly, these decision-makers are turning to cost-
effectiveness evidence to help them. Cost-effectiveness
analyses compare the costs and outcomes of two or
more clinical or other interventions to try to get ‘best
value’.
Examining cost-effectiveness
The researcher - usually an economist working with clin-
ical colleagues - would first add up the costs associated
with each intervention (the treatment itself plus other care
and support services used by patients) and subtract any
downstream monetary savings (perhaps because people
get healthier, use fewer services or avoid nursing home
admission). The researcher would also measure the out-
comes from each intervention, using the kind of symp-
tom, functioning and quality of life scales familiar to
clinical researchers.Correspondence: m.knapp@lse.ac.uk
Personal Social Services Research Unit, London School of Economics and
Political Science, London WC2A 2AE, UK
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and outcome data. For example, consider the choice be-
tween two medications for treating dementia. If one is
both cheaper and more effective than the other, it would
immediately look attractive to the hard-pressed budget-
holder because it improves health or wellbeing while sim-
ultaneously saving money. In such circumstances, in eco-
nomics parlance one medication dominates the other: it is
obviously more cost-effective. But the more cost-effective
option might not always get chosen, for there may be
other considerations, such as fairness, availability and pa-
tient preferences.Is it worth it?
Complications arise when one medication has better health
outcomes but higher costs (for the medication plus sup-
porting care) than the other. The quandary is whether the
better outcomes justify the higher cost. Whilst we would
all like to see better outcomes for dementia patients, we
must remember that resources are finite, and so commit-
ting extra resources to treating one patient will inevitably
mean fewer resources for other patients.
Judging whether the outcome difference justifies the
higher cost is not straightforward; indeed, it is a value
judgement. Someone has to look at the trade-off between
better outcome and higher cost and ask ‘Is it worth it?’
We all make these kinds of judgements in our everyday
lives: an option that pleases us most (has the best out-
comes) might be more expensive in time or money thans an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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An intervention can therefore be cost-effective even if
it costs more. Consider an example. Evaluation of cogni-
tive stimulation therapy in England found that patients
with mild-to-moderate dementia receiving this therapy
over 8 weeks had better cognitive and quality of life out-
comes than people getting standard care [1], but costs
were slightly higher. The economic analysis calculated
the incremental cost-effectiveness ratios for two out-
comes: £75 per 1-point improvement on the Mini Mental
State Examination and £23 per 1-point difference on
Quality of Life in Alzheimer's Disease [2]. Are these
amounts worth paying? We do not know definitively
because the answer depends on a decision-maker’s will-
ingness to pay these amounts for these particular out-
come gains.
Quality-adjusted life years and thresholds
An additional complication comes when a strategic
decision-maker must allocate resources between dif-
ferent clinical areas: outcome measures linked to
symptoms will be disorder-specific and hence incom-
parable across disorders. In these cases, an additional
generic (all-disorder) measure of outcome can be
used: the quality-adjusted life year (QALY) shows the
effects of treatment both in extending life and improv-
ing life quality. A commonly used tool is EQ-5D [3],
which performs well across most disorders. A tool that
is dementia-specific but nevertheless generates gen-
eric QALY measures stems from the DEMQOL [4,5].
In the START (STrAtegies for RelaTives) study, evaluat-
ing a coping strategy for family carers of dementia pa-
tients, QALYs were measured alongside clinical outcomes
[6]. The intervention was effective over 8 months in im-
proving carers’ mental health and health-related quality of
life. The economic evaluation found that, inter alia, costs
were slightly but not significantly higher for the interven-
tion group compared with treatment as usual, and that
the cost per additional QALY for carers was £6,000 [7].
Is that amount worth paying? Again, we do not imme-
diately know the answer. However, we can now refer to a
threshold value recommended by the health technology
assessment body for England and Wales, the National
Institute for Health and Care Excellence (NICE). NICE
has a framework to help decide whether better out-
comes are ‘worth’ the higher costs sometimes necessary
to achieve them; decisions are taken by expert groups
comprising clinicians, patients, researchers and the public
[8]. NICE would consider that a medication or other inter-
vention costing more than £20,000 per QALY is generally
not ‘worth it’ since the resources could be better spent
elsewhere in the healthcare system. The threshold is not a
rigid rule [9], but provides guidance in making toughchoices, and it reminds all of us - doctors, nurses, patients,
carers, taxpayers, voters - that resources are scarce.
By reference to this threshold, the START intervention
for dementia carers is certainly cost-effective over an
8-month period and, indeed, the 24-month results also
look encouraging [10].
Contributing to better health
This kind of analysis has become very common across
all clinical and health services research literatures [11],
although the number of cost-effectiveness studies in the
dementia field remains modest [12]. It should be stand-
ard evaluative practice for any new intervention. If (say)
a disease-modifying treatment for Alzheimer’s was to be
developed, an economic evaluation would need to cost the
diagnostic testing, treatment and other services, measure
any savings from delayed care home admission, and com-
bine these monetary data with evidence on gains in health,
quality of life and life-span. These would need to be com-
pared with costs, savings and outcomes for standard treat-
ment and care to judge both relative effectiveness and
value for money.
Economists work with clinical researchers to evaluate
whether medications, psychosocial therapies, care arrange-
ment, risk-reduction strategies or other interventions are
not only effective but also cost-effective. Remember that
the fundamental aim of a healthcare system is not to save
money, but to save and improve lives. However, the best
way to achieve this aim is to make best use of the re-
sources that are available, which in turn means getting an
understanding of cost-effectiveness and highlighting the
trade-offs between better outcomes and higher costs that
often have to be made.
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